elderly patients (> = 60 years) with Acute Myeloid Leukemia research hub

LAMSA2020: “A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly patients with acute myeloid leukemia in first remission”

This study looks at two different treatment combinations for older people (aged 60 and over) with a type of blood cancer called acute myeloid leukaemia (AML). It aims to find out which combination works better after their initial treatment to keep the cancer away.